Reduced effectiveness and comparable safety in biweekly vs. weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency: a phase IV non-inferiority threshold targeted trial - Sun, C; Lu, B; Liu, Y (Front Endocrinol (Lausanne), 2021)
et al.